Supersonic Imagine : SuperSonic Imagine : SuperSonic Imagine Announces a
Significant Financing Round - 28 million euros raised - FSI subscribes to half
the round alongside historical investors and two new arrivals
SuperSonic Imagine Announces a Significant Financing Round
28 million euros raised
FSI subscribes to half the round
alongside historical investors and two new arrivals
Paris, April 3^rd 2013, SuperSonic Imagine, a French ultrasound company, is
pleased to announce that it has raised €28million with €14million invested
by the FSI (French Investment Fund) alongside two new investors, Alto Invest
and KLSC (Kuwait Life Sciences Company) and a substantial subscription from
the company's historical investors.
Edmond de Rothschild Investment Partners, Auriga Partners, Omnes Capital
(formerly Crédit Agricole Private Equity), CDC Entreprises, NBGI Ventures,
Wellington Partners, iXO Private Equity, and Mérieux Développement, along with
Alto Invest and KLSC, are subscribing to €14 million.
SuperSonic Imagine will invest the funds to accelerate international sales and
marketing of its Aixplorer® ultrasound device, a product which originally
targeted women's health when it was launched in 2009, but which now covers all
fields of general radiology, with regulatory approval in all key international
Aixplorer's competitive advantages include exceptional image quality and
unique technologies such as: ShearWave(TM) Elastography and UltraFast(TM)
Doppler. ShearWave Elastography is the only modality available on any
ultrasound product which is able to detect tissue stiffness in a reproducible
and quantifiable manner. UltraFast Doppler, is unique in its ability to image
blood flow up to ten times faster than conventional color Doppler. This not
only provides more reliable diagnoses for the patient but it also
significantly accelerates workflow for the practitioner.
As a result of the expansion of its addressable market, SuperSonic Imagine
registered strong growth in 2012 with a turnover of €14million, up 40% from
the previous year, 80% of which came from international.
"Currently certified in 54 countries and with more than 500 units sold around
the globe, Aixplorer is a worldwide success. This new injection of funds will
allow us to take a leap forward in our commercial development with a
particular focus on the booming Chinese market," explained Jacques Souquet,
founder and CEO of SuperSonic Imagine.
"The FSI sees SuperSonic Imagine as a company with considerable potential for
growth based on revolutionary technological innovation that had its origins
from a successful technology transfer from top research institutions into a
great start up company. The FSI is pleased to provide SuperSonic Imagine the
funding it needs to pursue both its business and scientific development
worldwide," said Mailys Ferrere, Director of Investment at the FSI and member
of the FSI Executive Board.
Claude Cohen-Bacrie Executive VP & CTO of SuperSonic Imagine added that "This
investment will help us remain at the forefront of scientific and technical
innovation and affirm our clinical position through new research."
Currently, there is data from more than fifty clinical trials that prove the
benefits of ShearWave Elastography in improving ultrasound diagnoses for
various diseases including breast cancer, prostate cancer, chronic liver
disease, muscular disorders, thyroid nodules, and many more.
Abdominal, gynecological and pediatric imaging are also available on the
Aixplorer, and the results appear very promising.
Vascular imaging, launched in 2011 with UltraFast Doppler, has also been very
successful. Aixplorer's UltraFast Doppler is the only Doppler able to combine
Color Flow Imaging with Pulsed Wave Doppler in a single ultrasound mode. The
technology produces a complete vascular analysis in just a few seconds with an
unrivalled level of detail, improving the examination procedure and providing
more reliable diagnoses.
Gordon Waldron, Executive VP and CFO of SuperSonic Imagine, is pleased with
this new investment which is among the most significant private fundings in
the French healthcare sector in recent years. He added, "Since inception, we
have been primarily R&D focussed as SuperSonic brought the first innovation to
the ultrasound space in the past 20 years. Aixplorer has now become a mature
system with a range of applications that meet the needs of both general
imaging experts and their patients. Consequently, we will use these proceeds
to increase our sales and marketing footprint as we enter the growth and
execution phase of our development».
About SuperSonic Imagine -www.supersonicimagine.com
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is
an innovative, international company specializing in ultrasound medical
imaging. The company designs, develops, and markets a revolutionary ultrasound
system, Aixplorer®, with a unique ultrasound imaging technology, called
MultiWave(TM) Technology. This technology allows Aixplorer® to be the only
ultrasound system that images two types of waves to better characterize
tissue; an ultrasound wave to ensure impeccable image quality and a shear
wave, ShearWave(TM) Elastography, to compute and display true tissue stiffness
in real time by acquiring images nearly 200 times faster than conventional
In 2009, SuperSonic Imagine was granted 510(k) clearance by the Food and Drug
Administration in the United States and CE mark in Europe for the marketing of
Aixplorer®. Distribution agreements have been signed with prestigious
companies such as Hologic (Nasdaq : HOLX) for the breast market in the U.S.A.
and Canon (NYSE : CAJ) for Japan. SuperSonic Imagine's distribution network
has now more than 35 partners worldwide.
About French Investment Fund
FSI is a public limited company, 51% held by The Caisse des Dépôts group, and
49% held by The French State. As a prudent investor, FSI holds a minority
stake into French private companies that build valuable and competitive
strategies increasing French business opportunities.
More information to come on www.fonds-fsi.fr
About BPI France
OSEO, CDC Entreprises and French Investment Fund will go forward as a single
company, BPI France, known as French Public Investment Bank, as soon as merger
requirements, such as European Commission Compliance and Regulation, will be
fully integrated. This institution will offer a broad range of funding
solutions, debt instruments as well as equity's, not only dedicated to SMEs
and innovative companies but also to large-scale companies that foster French
economic growth from a strategic perspective.
More information to come on www.bpifrance.fr
About ALTO INVEST - www.altoinvest.fr
ALTO INVEST is an independent management company dedicated to investments in
SMEs. ALTO INVEST manages over € 300 million in retail and institutional funds
(FCPI, FIP and FCPR), invested in more than 100 European innovation-rich
companies representing a total turnover of € 6 billion and 40,000 employees.
Alto Invest is fully approved by the French financial authorities (Autorité
des Marchés Financiers) and is an active member of the French Asset Management
Association (Association Française de la Gestion Financière).
Kuwait Life Sciences Company (KLSC) is fully owned by National Technology
Enterprises Company (NTEC); a Kuwait Investment Authority (KIA) fully owned
company. KLSC aims to accelerate the transfer of best in-class technologies
and innovative business models practiced globally to match the needs of Kuwait
& the region, in addition to offering healthcare professionals with
distinguished opportunities for development and growth that match
international standards. To achieve this, KLSC looks for investment
opportunities in the areas of medical technology, diagnostics, pharmaceuticals
and healthcare services which address prevalent diseases in the MENA region.
KLSC also has a distribution arm to commercialize innovative medical
technologies mainly in laboratory diagnostics, surgical & Imaging, mobile
Health and screening programs. With regards to professional development, KLSC
has established the first healthcare academy in the GCC region offering
continuous medical education programs across all healthcare sectors.
For further information, visit the KLSC website at www.klsc.com.kw
SuperSonic Imagine H&B Communication Anne Hardy
Michele Debain Florence Portejoie firstname.lastname@example.org
Global Marketing Director email@example.com +33 (0)1 58 18 32 51
firstname.lastname@example.org +33 (0)1 58 18 32 58 +33 (0)6 13 56 23 96
+33 (0)4 42 99 24 32 +33 (0)6 88 84 81 74
Anne Descamps Elise Hermant
Havas Worldwide Havas Worldwide
+33 (0)1 58 47 93 32 +33 (0)1 58 47 84 09
+33 (0)1 80 81 50 05
Tel:(+965) 22 49 09 69
Cell: (+965) 99 44 50 80
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Supersonic Imagine via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.